Table 2.
In vitro properties assessed in control and AA-MSCs.
| Author (s) | Year | Groups (n=): controls vs. AA (severity) | Prior treatment (Yes/No/NR) | Proliferation | Differentiation | Surface marker expression | Immunomodulatory ability | Hematopoietic support | Other | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| adipo | osteo | chondro | |||||||||
| Sharma et al. (25) | 2021 | 5 vs.5 (3 nSAA, 2 SAA) | No | • | • | • | • | • | • | Metabolic activity, appearance with immunofluorescence | |
| Li, H. et al. (26) | 2021 | 5 vs. 5 | NR | • | • | ||||||
| Li, H. et al. (27) | 2020 | 9 vs. 9 | NR | • | • | ||||||
| Li, S. et al. (28) | 2020 | 9 vs. 21 (SAA) | No | • | • | • | • | Apoptotic tendency, PTH levels, T-cell PTH-1R and Wnt factor expression | |||
| Huo et al. (29) | 2020 | 14 vs. 15 (6 nSAA, 9 SAA) | No | • | • | • | • | • | • | Apoptotic tendency, cellular senescence, cell migration, gene expression profile, appearance with immunofluorescence | |
| Chao et al. (30) | 2018 | 5 vs. 5 | No | • | • | Apoptotic tendency | |||||
| Chaturvedi et al. (31) | 2018 | 29 vs. 29 | NR | • | • | • | • | ||||
| Lu et al. (32) | 2017 | 19 vs. 28 (24 nSAA, 4 SAA) | NR | • | • | Gene expression profile | |||||
| Michelozzi et al. (33) | 2017 | 7 vs. 8 (2 nSAA, 6 SAA) | Yes (all, prior IST/HSCT) | • | • | • | • | • | • | Appearance with immunofluorescence | |
| Wei et al. (34) | 2016 | 12 vs. 12 (7 nSAA, 5 SAA) | No | • | • | ||||||
| Cheng et al. (35) | 2015 | 6 vs. 10 | NR | • | • | • | Apoptotic tendency, cellular senescence | ||||
| Hamzic et al. (36) | 2015 | 9 vs. 22 (9 nSAA, 13 SAA) | Yes (9/22, prior IST) | • | • | • | Appearance with immunofluorescence | ||||
| Bueno et al. (37) | 2014 | 7 vs. 9 | No | • | • | • | • | • | |||
| El-Mahgoub et al. (38) | 2014 | 5 vs.5 | NR | • | • | • | • | ||||
| Jiang et al. (39) | 2014 | 8 vs. 10 | NR | • | • | • | • | • | |||
| Tripathy et al. (40) | 2014 | 10 vs.10 | NR | • | • | • | |||||
| Zhao et al. (41) | 2014 | 7 vs. 6 | No | • | • | • | |||||
| Li, J et al. (42) | 2012 | 11 vs. 15 | No | • | • | • | • | Appearance with immunofluorescence | |||
| Li, J et al. (43) | 2012 | 20 vs. 21 (SAA) | No | • | • | • | • | Apoptotic tendency, gene expression profile, appearance with immunofluorescence | |||
| Chao et al. (44) | 2010 | 5 vs. 5 (SAA) | No | • | • | • | • | ||||
| Shipounova et al. (45) | 2009 | 54 vs. 26 (10 nSAA, 16 SAA) | Yes (17/26 prior treatment) | • | • | • | • | bFGF, ANG-1, VCAM-1, VEGF, BMP, IGF-1 expression | |||
| Xu et al. (46) | 2009 | 15 vs. 34 (8 nSAA, 19 SAA, 7 vSAA) | Yes (19/34 prior IST) | • | • | • | |||||
| Bacigalupo et al. (47) | 2005 | 19 vs. 19 (SAA) | Yes (16/19, prior IST) | • | • | • | • | • | • | • | |
Bullet point means that this particular outcome in the column is studied in the discussed article. NR, Not reported.